Description: InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. The company operates in two segments, Pharmaceuticals and Consumer Wellness. It engages in the research and development of CBD loaded exosomes, as well as operates LPT CBD-loaded liposome platform that facilitates exact dosing and the prolonged and controlled release of CBD into the blood stream for epilepsy and pain management. The company is also involved in the development and sale of CBD-integrated pharmaceuticals and topical products. In addition, it develops and markets a portfolio of self-care products for healthier lifestyle. The company offers its products under the Innocan Pharma, R&G Relief & Go, Shir, Synony, and Add On trade names. InnoCan Pharma Corporation was incorporated in 2018 and is headquartered in Calgary, Canada.
Home Page: innocanpharma.com
1015, 926 – 5 Avenue SW
Calgary,
AB
T2P 0N7
Canada
Phone:
403-777-1519
Officers
| Name | Title |
|---|---|
| Mr. Ron Mayron | Executive Chairman |
| Ms. Iris Bincovich | CEO & Director |
| Mr. Nelson Harvey Halpern F.C.A., FCPA | Chief Financial Officer |
| Mr. Roni Kamhi | COO & CEO of BI Sky Global and Director |
| Mr. Eyal Flom L.L.M., M.B.A. | Director & Company Secretary |
| Mr. Yoram Drucker | Founder & Executive VP of Business Development |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 8.2241 |
| Price-to-Sales TTM: | 1.7098 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |